Clinical Trial Update: To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating SB-649868 at 10, 30, and 60 mg in adults with primary insomnia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• SB-649868

Snippet

Sponsor: GlaxoSmithKline | Conditions: Sleep Initiation and Maintenance Disorders | Phase 2 | Status: COMPLETED